This growing body of evidence not only reinforces the therapeutic relevance of DPP-4 inhibitors but also underscores the intricate interplay between metabolic signaling pathways and neurological outcomes, offering a nuanced perspective on the comprehensive impact of these agents in diabetes management and beyond. Here, DPP4 is linked to diabetes mellitus.